<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60503">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02318303</url>
  </required_header>
  <id_info>
    <org_study_id>GPL/CT/2014/004/II</org_study_id>
    <secondary_id>IND Number: 123164</secondary_id>
    <nct_id>NCT02318303</nct_id>
  </id_info>
  <brief_title>To Study GSP 301 in Patients With Seasonal Allergic Rhinitis</brief_title>
  <official_title>A Double-blind, Randomized, Parallel-group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Two Different Strengths and Regimens of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Comparators), in Subjects (12 Years of Age and Older) and With Seasonal Allergic Rhinitis (SAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Pharmaceuticals Ltd. India</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glenmark Pharmaceuticals Ltd. India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the two different strengths and dose regimen of GSP 301 to be effective in
      treatment of seasonal allergic rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in rTNSS from baseline to end of treatment</measure>
    <time_frame>14 days</time_frame>
    <description>Average AM and PM score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in average AM and PM subject-reported 12-hour instantaneous Total Nasal Symptoms Score (iTNSS)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 12-hour reflective Total Ocular Symptom Score (rTOSS)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of action will be assessed by comparing change from baseline in post-treatment TNSS</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">1106</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Placebo nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo nasal spray for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSP 301-1 NS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSP 301-1 nasal spray for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSP 301-2 NS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSP 301-2 nasal spray for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olopatadine hydrochloride NS-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator 1 nasal spray for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olopatadine hydrochloride NS-2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator 2 nasal spray for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone furoate NS-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator 3 nasal spray for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone furoate NS-2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator 4 nasal spray for two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSP 301-1 NS</intervention_name>
    <arm_group_label>GSP 301-1 NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSP 301-2 NS</intervention_name>
    <arm_group_label>GSP 301-2 NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo nasal spray</intervention_name>
    <arm_group_label>Placebo nasal spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine hydrochloride NS-1</intervention_name>
    <arm_group_label>Olopatadine hydrochloride NS-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine hydrochloride NS-2</intervention_name>
    <arm_group_label>Olopatadine hydrochloride NS-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate NS-1</intervention_name>
    <arm_group_label>Mometasone furoate NS-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate NS-2</intervention_name>
    <arm_group_label>Mometasone furoate NS-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Aged ≥12 years and older inclusive of either sex.

          2. Documented clinical history of SAR (for at least 2 years preceding the Screening
             Visit [Visit 1]) with exacerbations (clinical evidence of active symptoms) during the
             study season for the mountain cedar pollen

          3. A 12-hour reflective TNSS ≥ 8 out of a possible 12 and a congestion score of ≥ 2 for
             the AM assessment at the Screening Visit (Visit 1).

        Key Exclusion Criteria:

          1. Pregnant or lactating women.

          2. Plans to travel outside the known pollen area for the investigative site for &gt; 24
             hours during the last 7 days of run in period.

          3. History of nasal polyps of other clinically significant respiratory tract
             malformations, recent nasal biopsy, nasal trauma (such as nasal piercing) or surgery,
             atopic dermatitis or rhinitis medicamentosa.

          4. History of anaphylaxis and/or other severe local reaction(s) to skin testing.

          5. History of positive test for HIV, Hepatitis B or Hepatitis C infection.

          6. Documented evidence of acute or significant chronic sinusitis or chronic purulent
             postnasal drip.

          7. Subjects with an active pulmonary disorder or infection.

          8. Subjects with posterior subcapsular cataracts or glaucoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudeesh Tantry, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Glenmark Pharmaceuticals Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glenmark Investigational Site 10</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 5</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 6</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 2</name>
      <address>
        <city>Kerrville</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 7</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 3</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 4</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 8</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 9</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 1</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>July 14, 2016</lastchanged_date>
  <firstreceived_date>December 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
